Avalyn Pharma closed its IPO, raising $345 million with 19.17 million shares priced at $18 each.
Quiver AI Summary
Avalyn Pharma Inc. announced the successful closing of its initial public offering (IPO) on May 1, 2026, raising a total of $345 million by offering 19,166,667 shares of common stock at an IPO price of $18.00 per share. This total includes the underwriters' full exercise of an overallotment option for an additional 2,500,000 shares. The company’s stock is now listed on the Nasdaq Global Select Market under the ticker symbol “AVLN.” Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities served as joint book-running managers for the IPO, which was made effective through a registration statement filed with the SEC. The press release clarifies that it does not constitute an offer to sell or solicitate offers to buy the securities involved.
Potential Positives
- Avalyn Pharma successfully closed its initial public offering (IPO), raising a total of $345 million, indicating strong demand and investor interest.
- The company’s stock is now listed on the Nasdaq Global Select Market, providing enhanced visibility and credibility in the financial markets.
- The IPO included the full exercise of the underwriters' overallotment option, demonstrating confidence from the underwriters in Avalyn's growth potential.
Potential Negatives
- Closing of the initial public offering could indicate that the company needs capital, which may raise concerns about financial stability or operational viability.
- The press release does not provide any information about the use of proceeds from the IPO, leaving potential investors uncertain about how the funds will be allocated.
- Being a clinical-stage company, there is no guarantee that the anticipated therapies will successfully complete clinical trials or gain regulatory approval, posing a risk to investors.
FAQ
What was the IPO price for Avalyn Pharma's shares?
The IPO price for Avalyn Pharma's shares was $18.00 per share.
How many shares were offered in Avalyn Pharma's IPO?
Avalyn Pharma offered a total of 19,166,667 shares in its IPO.
What is the gross proceeds amount from Avalyn's IPO?
The aggregate gross proceeds from Avalyn's IPO were $345 million.
Where is Avalyn Pharma's stock listed?
Avalyn Pharma's common stock is listed on the Nasdaq Global Select Market under the ticker symbol “AVLN.”
Who were the managers for Avalyn Pharma's offering?
Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities acted as joint book-running managers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the closing of its initial public offering (IPO) of an aggregate 19,166,667 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 2,500,000 additional shares, at IPO price of $18.00 per share. All of the shares of common stock were offered by Avalyn.
The aggregate gross proceeds from the offering of the initial shares and the additional shares described above, before deducting underwriting discounts and commissions and other offering expenses, were $345 million. Avalyn’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “AVLN.”
Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission and was declared effective on April 29, 2026. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from:
Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, New York, NY 10014, telephone: 1-866-718-1649, email: [email protected] ; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, email: [email protected] ; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, telephone: (888) 474-0200, email: [email protected] ; or Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Ave., New York, New York 10017, telephone: (212) 518-9544, email: [email protected] .
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact:
Kat Lippincott, Deerfield Group
[email protected]
[email protected]
Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
[email protected]
